WO1996017942A1 - Production de peptides au moyen de proteines de fusion de recombinaison - Google Patents
Production de peptides au moyen de proteines de fusion de recombinaison Download PDFInfo
- Publication number
- WO1996017942A1 WO1996017942A1 PCT/US1995/015800 US9515800W WO9617942A1 WO 1996017942 A1 WO1996017942 A1 WO 1996017942A1 US 9515800 W US9515800 W US 9515800W WO 9617942 A1 WO9617942 A1 WO 9617942A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fusion protein
- protein construct
- seq
- solution
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 216
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 85
- 238000004519 manufacturing process Methods 0.000 title description 11
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title description 6
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 162
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 160
- 239000012634 fragment Substances 0.000 claims abstract description 109
- 102000003846 Carbonic anhydrases Human genes 0.000 claims abstract description 88
- 108090000209 Carbonic anhydrases Proteins 0.000 claims abstract description 88
- 238000000034 method Methods 0.000 claims abstract description 87
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 56
- 229920001184 polypeptide Polymers 0.000 claims abstract description 54
- 230000001376 precipitating effect Effects 0.000 claims abstract description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 90
- 238000003776 cleavage reaction Methods 0.000 claims description 71
- 230000007017 scission Effects 0.000 claims description 63
- 210000004027 cell Anatomy 0.000 claims description 59
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 51
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 33
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 150000007523 nucleic acids Chemical group 0.000 claims description 19
- 108090000190 Thrombin Proteins 0.000 claims description 18
- 229960004072 thrombin Drugs 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 230000002255 enzymatic effect Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 12
- 229940088598 enzyme Drugs 0.000 claims description 12
- 239000000199 parathyroid hormone Substances 0.000 claims description 12
- 108010013369 Enteropeptidase Proteins 0.000 claims description 11
- -1 benzenesulfonamide compound Chemical class 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 11
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 claims description 10
- 239000002904 solvent Substances 0.000 claims description 10
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 claims description 10
- 102100029727 Enteropeptidase Human genes 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 7
- 230000003196 chaotropic effect Effects 0.000 claims description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 229960000571 acetazolamide Drugs 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 6
- 108010059378 Endopeptidases Proteins 0.000 claims description 5
- 102000005593 Endopeptidases Human genes 0.000 claims description 5
- 239000003599 detergent Substances 0.000 claims description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 5
- 235000011152 sodium sulphate Nutrition 0.000 claims description 5
- 229940124530 sulfonamide Drugs 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 239000004202 carbamide Substances 0.000 claims description 4
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 3
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 3
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 claims description 2
- 102000005572 Cathepsin A Human genes 0.000 claims description 2
- 108010059081 Cathepsin A Proteins 0.000 claims description 2
- 108090000317 Chymotrypsin Proteins 0.000 claims description 2
- 108010074860 Factor Xa Proteins 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- 108090000783 Renin Proteins 0.000 claims description 2
- 102100028255 Renin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 239000003957 anion exchange resin Substances 0.000 claims description 2
- 229960002376 chymotrypsin Drugs 0.000 claims description 2
- 108090001092 clostripain Proteins 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 108090000787 Subtilisin Proteins 0.000 claims 1
- 102000044159 Ubiquitin Human genes 0.000 claims 1
- 229960001322 trypsin Drugs 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 14
- 238000002955 isolation Methods 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 110
- 150000001413 amino acids Chemical class 0.000 description 60
- 229940024606 amino acid Drugs 0.000 description 58
- 235000001014 amino acid Nutrition 0.000 description 58
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 45
- 230000000692 anti-sense effect Effects 0.000 description 33
- 108020004414 DNA Proteins 0.000 description 32
- 101710142969 Somatoliberin Proteins 0.000 description 31
- 102100022831 Somatoliberin Human genes 0.000 description 30
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
- 101000760643 Homo sapiens Carbonic anhydrase 2 Proteins 0.000 description 25
- 102000057327 human CA2 Human genes 0.000 description 23
- 238000006243 chemical reaction Methods 0.000 description 22
- 108091016366 Histone-lysine N-methyltransferase EHMT1 Proteins 0.000 description 20
- 102100036893 Parathyroid hormone Human genes 0.000 description 19
- 238000005119 centrifugation Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 17
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 16
- 239000008188 pellet Substances 0.000 description 15
- 238000001556 precipitation Methods 0.000 description 15
- 238000000855 fermentation Methods 0.000 description 14
- 230000004151 fermentation Effects 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 13
- 102100035043 Histone-lysine N-methyltransferase EHMT1 Human genes 0.000 description 12
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 102100040918 Pro-glucagon Human genes 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- 229920002873 Polyethylenimine Polymers 0.000 description 9
- 229960000583 acetic acid Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 108700004121 sarkosyl Proteins 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 229960002180 tetracycline Drugs 0.000 description 7
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 6
- YXXPVUOMPSZURS-ZLIFDBKOSA-N Ala-Trp-Leu Chemical compound C1=CC=C2C(C[C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](C)N)=CNC2=C1 YXXPVUOMPSZURS-ZLIFDBKOSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 241000672609 Escherichia coli BL21 Species 0.000 description 6
- LLWQVJNHMYBLLK-CDMKHQONSA-N Gly-Thr-Phe Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LLWQVJNHMYBLLK-CDMKHQONSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- AFPFGFUGETYOSY-HGNGGELXSA-N His-Ala-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AFPFGFUGETYOSY-HGNGGELXSA-N 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 108010009298 lysylglutamic acid Proteins 0.000 description 6
- 229930182817 methionine Natural products 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- 101150093139 ompT gene Proteins 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 239000013592 cell lysate Substances 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000005772 leucine Nutrition 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- KSCVLGXNQXKUAR-JYJNAYRXSA-N Tyr-Leu-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O KSCVLGXNQXKUAR-JYJNAYRXSA-N 0.000 description 4
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 235000009582 asparagine Nutrition 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 3
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108010079364 N-glycylalanine Proteins 0.000 description 3
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 3
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 229960001153 serine Drugs 0.000 description 3
- 235000004400 serine Nutrition 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 3
- OZRFYUJEXYKQDV-UHFFFAOYSA-N 2-[[2-[[2-[(2-amino-3-carboxypropanoyl)amino]-3-carboxypropanoyl]amino]-3-carboxypropanoyl]amino]butanedioic acid Chemical compound OC(=O)CC(N)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(O)=O OZRFYUJEXYKQDV-UHFFFAOYSA-N 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 2
- SGYSTDWPNPKJPP-GUBZILKMSA-N Arg-Ala-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SGYSTDWPNPKJPP-GUBZILKMSA-N 0.000 description 2
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 2
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 2
- 102400000113 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000701832 Enterobacteria phage T3 Species 0.000 description 2
- PXXGVUVQWQGGIG-YUMQZZPRSA-N Glu-Gly-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N PXXGVUVQWQGGIG-YUMQZZPRSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
- RXVOMIADLXPJGW-GUBZILKMSA-N His-Asp-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RXVOMIADLXPJGW-GUBZILKMSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- NEEOBPIXKWSBRF-IUCAKERBSA-N Leu-Glu-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O NEEOBPIXKWSBRF-IUCAKERBSA-N 0.000 description 2
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 2
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010033276 Peptide Fragments Proteins 0.000 description 2
- 102000007079 Peptide Fragments Human genes 0.000 description 2
- HOYQLNNGMHXZDW-KKUMJFAQSA-N Phe-Glu-Arg Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O HOYQLNNGMHXZDW-KKUMJFAQSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 101000978265 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Carboxypeptidase Y Proteins 0.000 description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000001851 biosynthetic effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 108010050848 glycylleucine Proteins 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 2
- 239000012134 supernatant fraction Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- YUXKOWPNKJSTPQ-AXWWPMSFSA-N (2s,3r)-2-amino-3-hydroxybutanoic acid;(2s)-2-amino-3-hydroxypropanoic acid Chemical compound OC[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O YUXKOWPNKJSTPQ-AXWWPMSFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YLOOYNJUAMLMAA-UHFFFAOYSA-N 2-amino-n-(2-nitrophenyl)acetamide Chemical compound NCC(=O)NC1=CC=CC=C1[N+]([O-])=O YLOOYNJUAMLMAA-UHFFFAOYSA-N 0.000 description 1
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 1
- KRAFHNPGRHNJAR-UHFFFAOYSA-N 2-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1SC#N KRAFHNPGRHNJAR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- NINQYGGNRIBFSC-CIUDSAMLSA-N Ala-Lys-Ser Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CO)C(O)=O NINQYGGNRIBFSC-CIUDSAMLSA-N 0.000 description 1
- DRARURMRLANNLS-GUBZILKMSA-N Ala-Met-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O DRARURMRLANNLS-GUBZILKMSA-N 0.000 description 1
- 108010011667 Ala-Phe-Ala Proteins 0.000 description 1
- MAZZQZWCCYJQGZ-GUBZILKMSA-N Ala-Pro-Arg Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O MAZZQZWCCYJQGZ-GUBZILKMSA-N 0.000 description 1
- ADSGHMXEAZJJNF-DCAQKATOSA-N Ala-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N ADSGHMXEAZJJNF-DCAQKATOSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 1
- WKPXXXUSUHAXDE-SRVKXCTJSA-N Arg-Pro-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O WKPXXXUSUHAXDE-SRVKXCTJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 1
- UYCPJVYQYARFGB-YDHLFZDLSA-N Asn-Phe-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O UYCPJVYQYARFGB-YDHLFZDLSA-N 0.000 description 1
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 1
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 1
- JHFNSBBHKSZXKB-VKHMYHEASA-N Asp-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(O)=O JHFNSBBHKSZXKB-VKHMYHEASA-N 0.000 description 1
- LIVXPXUVXFRWNY-CIUDSAMLSA-N Asp-Lys-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O LIVXPXUVXFRWNY-CIUDSAMLSA-N 0.000 description 1
- UKGGPJNBONZZCM-WDSKDSINSA-N Asp-Pro Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O UKGGPJNBONZZCM-WDSKDSINSA-N 0.000 description 1
- PLOKOIJSGCISHE-BYULHYEWSA-N Asp-Val-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLOKOIJSGCISHE-BYULHYEWSA-N 0.000 description 1
- 102100023927 Asparagine synthetase [glutamine-hydrolyzing] Human genes 0.000 description 1
- 108010070255 Aspartate-ammonia ligase Proteins 0.000 description 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 1
- 101710140866 Caltrin Proteins 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 101800004295 Glucagon-like peptide 1(7-36) Proteins 0.000 description 1
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 1
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 1
- YSDLIYZLOTZZNP-UWVGGRQHSA-N Gly-Leu-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN YSDLIYZLOTZZNP-UWVGGRQHSA-N 0.000 description 1
- IUKIDFVOUHZRAK-QWRGUYRKSA-N Gly-Lys-His Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IUKIDFVOUHZRAK-QWRGUYRKSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- JWTKVPMQCCRPQY-SRVKXCTJSA-N His-Asn-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O JWTKVPMQCCRPQY-SRVKXCTJSA-N 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 1
- MSFITIBEMPWCBD-ULQDDVLXSA-N Leu-Val-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 MSFITIBEMPWCBD-ULQDDVLXSA-N 0.000 description 1
- UQRZFMQQXXJTTF-AVGNSLFASA-N Lys-Lys-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O UQRZFMQQXXJTTF-AVGNSLFASA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100202339 Mus musculus Slc6a13 gene Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 101100293593 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nar-1 gene Proteins 0.000 description 1
- 102400000050 Oxytocin Human genes 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100034367 Putative peptide YY-2 Human genes 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 101100202330 Rattus norvegicus Slc6a11 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 1
- 102100027287 Serpin H1 Human genes 0.000 description 1
- 108050008290 Serpin H1 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- PQLXHSACXPGWPD-GSSVUCPTSA-N Thr-Asn-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PQLXHSACXPGWPD-GSSVUCPTSA-N 0.000 description 1
- WTMPKZWHRCMMMT-KZVJFYERSA-N Thr-Pro-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(O)=O WTMPKZWHRCMMMT-KZVJFYERSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- RWOGENDAOGMHLX-DCAQKATOSA-N Val-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C(C)C)N RWOGENDAOGMHLX-DCAQKATOSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010041407 alanylaspartic acid Proteins 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- KFGRVLINLVVMJA-MITYVQBRSA-N chembl440262 Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 KFGRVLINLVVMJA-MITYVQBRSA-N 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012938 design process Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 108010025306 histidylleucine Proteins 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000058004 human PTH Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 108700003621 insect attacin antibacterial Proteins 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 101150011498 lad gene Proteins 0.000 description 1
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 108010044348 lysyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940067741 sodium octyl sulfate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 108010056001 somatotropin releasing hormone (1-29) Proteins 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
- 229940006486 zinc cation Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- any foreign protein in any microbial host is theoretically possible, the stability of the protein produced often limits such practice and results in a low yield.
- small foreign proteins and oligopeptides are not easily overproduced in most cellular hosts.
- Expression of a small peptide in a host cell raises the possibility that the host will assimilate the polypeptide.
- small peptides have been expressed as fusion proteins with a second larger peptide, such as a peptide marker (e.g., beta- galactosidase or chloramphenicol acetyl transferase) . While the resulting fusion protein may not be readily assimilated, isolation and purification of the desired protein is often not very efficient or effective.
- a peptide marker e.g., beta- galactosidase or chloramphenicol acetyl transferase
- the present invention provides a method for the production of a recombinant peptide which employs a fusion protein construct including a carbonic anhydrase and a variable fused polypeptide.
- the carbonic anhydrase is a mammalian carbonic anhydrase (mCA) .
- the carbonic anhydrase and the variable fused polypeptide may be linked together by a cleavage site.
- the cleavage site is an amino acid or sequence of amino acids which results in the protein construct being selectively cleaved on treatment by a cleavage agent.
- the cleavage agent may be a chemical reagent, e.g.
- the cleavage agent may be also be an endopeptidase which cleaves the construct at a specific point in relation to a particular amino acid or sequence of amino acids ("an enzymatic cleavage site") .
- One embodiment of the invention is directed to a method of producing a peptide which includes precipitating the fusion protein construct.
- the precipitated construct may be resolubilized.
- the fragment containing the carbonic anhydrase (“carbonic anhydrase fragment”) may be removed by chromatography, filtration or, preferably, by precipitation.
- a second embodiment provides a method of producing a peptide which includes (i) cleaving the fusion protein construct to produce a soluble carbonic anhydrase fragment and a soluble variable fused polypeptide fragment, and (ii) precipitating the carbonic anhydrase fragment .
- the carbonic anhydrase fragment includes the carbonic anhydrase and may also include other amino acids residues, e.g., from an interconnecting peptide or a chemical moiety created by the cleavage reaction.
- the variable fused polypeptide fragment includes at least one copy of a target peptide and may also include additional amino acid residues such as an N-terminal or C-terminal tail sequence or an intraconnecting peptide. Where the variable fused polypeptide fragment includes more than one copy of a target peptide, the target peptides are typically linked by an intraconnecting peptide which includes a cleavage site.
- a third embodiment of the invention provides a method of producing a peptide which includes expressing the fusion protein construct as part of an inclusion body in a host cell, e.g., an E. coli host cell, and isolating the fusion protein construct.
- the fusion protein construct typically includes at least 2 copies of a target peptide.
- the fusion protein construct includes target peptide corresponding to a peptide selected from the group consisting of GRF(l-44) (SEQ ID NO:20), GLPl(7-34) (SEQ ID NO:21) and PTH(l-34) (SEQ ID NO:22)
- GRF(l-44) SEQ ID NO:20
- GLPl(7-34) SEQ ID NO:21
- PTH(l-34) SEQ ID NO:22
- GRF(1-41) SEQ ID NO:23
- GLP1 (7-34) SEQ ID NO:21
- PTH(l-34) SEQ ID NO:22
- GRF(1-41) SEQ ID NO:23
- GLP1 (7-34) SEQ ID NO:21
- PTH(l-34) SEQ ID NO:22
- the sequences for amino acids 1-44 of growth hormone releasing factor (GRF(l-44) (SEQ ID NO:20)) and amino acids 1-36 of Glucagon-like Peptide 1 (GLPKl-36) SEQ ID NO:24)
- Another embodiment of the invention provides a method of producing a peptide which includes cleaving the fusion protein construct to produce a carbonic anhydrase fragment and a variable fused polypeptide fragment.
- the carbonic anhydrase fragment and the variable fused polypeptide fragment are precipitated.
- the precipitated fragments may be extacted with with a solvent which includes an organic component to recover the variable fused polypeptide fragment.
- the invention also provides an inclusion body containing the fusion protein construct expressed in a host cell, e.g., an E. coli host cell.
- the fusion protein construct includes a carbonic anhydrase and a target peptide.
- the target peptide preferably includes at least one copy of an amino acid sequence corresponding to a peptide selected from the group consisting of GRF(1-41) (SEQ ID NO:23), GLPK7-34) (SEQ ID N0:21) and PTH(l-34) (SEQ ID NO:22) .
- the invention also provides a fusion protein construct which includes the carbonic anhydrase and a target peptide.
- the target peptide includes an amino acid sequence corresponding to a peptide selected from the group consisting of GRF(1-41) (SEQ ID NO:23) , GLPK7-34) (SEQ ID NO:21) and PTH(l-34) (SEQ ID NO:22) .
- FIG. 1 depicts the various formulas for variable fused polypeptides formed of multiple units of target peptides.
- the expression of a foreign protein by interaction of recombinant vectors with the biosynthetic machinery of host cells or host organisms is a well-known technique for biochemical protein synthesis.
- the present invention utilizes a novel modification of this expression technique in combination with a carbonic anhydrase-based fusion protein construct to establish a new, low cost, highly efficient method for the large scale biological synthesis of peptides.
- the method makes it possible to design processes for the isolation and/or purification of a recombinant peptide based solely on chemical methods, i.e. without requiring affinity chromatography or other chromatographic steps.
- the fusion protein construct also permits the use of a ligand immobilized affinity separation technique if desired. The method eliminates expensive machinery and reagents, long synthetic times, low reaction efficiency and produces fewer faulty copies and a higher yield of the product peptide, than the solid phase peptide synthesis.
- the method of the invention incorporates a combination of cellular factors and biologic compositions that enable ready expression of foreign proteins by biological systems. Because the expressed fusion protein construct incorporates a binding protein, carbonic anhydrase, subversion of the particular identity of the target peptide by the expression mechanism of the cell or organism is not permitted. Variation in expression efficiency is minimized. The preferred inductive expression mechanism allows production of peptide constructs that might otherwise be toxic to host cells.
- the method of the invention also incorporates factors that contribute substantially to the efficiency, capacity and yield of the purification technique.
- the solubility properties of the carbonic anhydrase and fusion construct including the carbonic anhydrase facilitate a clean, complete separation of the variable fused polypeptide from other constituents.
- the relatively low molecular weight of the carbonic anhydrase permits a high capacity and efficiency per unit weight of the fusion construct. Because the method does not require any special reagents or reactions, the production of undesirable side products is avoided.
- the size of the fusion protein construct will vary depending on the nature and number of copies of the target peptide.
- the fusion protein construct is large enough to avoid degradation by the host cell (e.g., at least about 60 to 80 amino acid residues) and not so large that it can not be effectively expressed by the host cell.
- the fusion protein construct will have a molecular weight of up to about 500,000 although larger constructs are also within the scope of the present invention.
- the size of the fusion protein construct is chosen such that it may be expressed by the host cell so as to avoid introducing errors in the protein sequence. This places practical limitations on the number of copies of the target peptide present in a given construct . The actual number will vary depending on the size and nature of a particular target peptide within the limitations set by the factors discussed above.
- the carbonic anhydrase may be derived from a variety of sources. Suitable sources include vertebrates and in particular mammalian sources, e.g., a human carbonic anhydrase (hCA) , a rat carbonic anhydrase, a feline carbonic anhydrase, an equine carbonic anhydrase or a bovine carbonic anhydrase.
- hCA human carbonic anhydrase
- a rat carbonic anhydrase e.g., a rat carbonic anhydrase
- feline carbonic anhydrase equine carbonic anhydrase
- bovine carbonic anhydrase derived from other mammalian species
- An example of a suitable carbonic anhydrase is human carbonic anhydrase II ("hCAII"; see, Taylor et al., Biochemistry, 9 . , 2638 (1970)) .
- the carbonic anhydrase may also be a modified functional version of a carbonic anhydrase.
- the modified functional version will retain a carbonic anhydrase' s capability of being precipitated as a function of solution conditions, e.g. at a particular pH or as a function of metal ion or salt concentration. Modified versions which can be precipitated from a wide variety of solutions by adjusting the pH of the solution to between about 3.2 and about 6.0, more preferably to between about 3.5 and about 5.5, are preferred.
- the modified functional version typically also retains the ability of a carbonic anhydrase to strongly bind with the inhibitors, benzenesulfonamide, acetazolamide, or derivatives thereof.
- a detailed discussion of the binding properties of carbonic anhydrases with respect to sulfanilamide and acetazolamide inhibitors is set forth in International Application No. PCT/US91/04511, which is hereby incorporated by reference.
- suitably modified carbonic anhydrases include functional substitution mutants which (I) do not contain methionine, (II) have all or some glutamates replaced by another negatively charged amino acid, preferably aspartate, (III) have all or some arginines replaced by another positively charged amino acid, preferably lysine, (IV) have all or some asparagines replaced by another amino acid, preferably glutamine, (V) have methionine replaced by another amino acid, preferably alanine, serine, cysteine, threonine or leucine, or (VI) have cysteine replaced by another amino acid, preferably serine, threonine, leucine or alanine.
- suitably modified versions of carbonic anhydrase also include polypeptides representing a functional fragment of a carbonic anhydrase such as hCAII, such as but not limited to hCAII C-terminated at cysteine 205, asparagine 231, methionine 240, or leucine 250 or N-terminated at proline 21 or glycine 25.
- the functional fragment retains the ability of a carbonic anhydrase to be precipitated from a wide range of solutions by adjusting the pH.
- substitution mutants of hCAII and substitution mutants of the functional fragments of hCAII having the following substitutions: i. hCAII with all or some glutamate amino acid residues replaced by another negatively charged amino acid (AA) , preferably an aspartic acid residue, ii. hCAII with all or some arginine AA residues replaced by another positively charged AA, preferably a lysine residue, iii.
- hCAII or a functional fragment thereof with one or more of the following modifications to the AA positions at [N11X, G12X] (asparagine glycine) , [N62X, G63X] , [N231X, G232X] , M240X (methionine) , or C205X (cysteine) modified as follows (where those AA positions are present in a given fragment) : the asparagine is changed to glutamine or glycine is changed to alanine, methionine is changed to alanine, serine, cysteine, threonine or leucine, and cysteine is changed to serine threonine, leucine or alanine.
- the carbonic anhydrase and fusion proteins including the carbonic anhydrase preferably are capable of being precipitated from a wide range of solutions by adjusting the pH of the solution to between about 3.2 and about 6.0, preferably between about 3.5 and about 5.5, and more preferably between about 4.0 and about
- solutions from which the carbonic anhydrase can be precipitated using this method include solutions containing polyethyleneimine, urea (e.g., at least about 2M) or guanidine hydrochloride (e.g., at least about 2M) .
- the carbonic anhydrase remains soluble in a wide variety of solutions outside of the pH range of about 3.2 to about 6.0.
- variable fused polypeptide may have several forms (see e.g., Figure 1) .
- the intraconnecting peptide usually but not necessarily differs in structure and selectivity from the interconnecting peptide (which links the carbonic anhydrase and the variable fused polypeptide) .
- the intraconnecting peptide When different, the intraconnecting peptide nevertheless has the same general function as the interconnecting peptide so that two different cleavage agents of an enzymatic or chemical nature will separately cleave the variable fused polypeptide from the carbonic anhydrase and cleave the individual target peptides from each other.
- the third form is a single unit composed of several (i.e., two or more) identical or different target peptides tandemly interlinked together by innerconnecting peptides.
- the fourth form is composed of repeating multiple tandem units linked together by intraconnecting peptides wherein each unit contains the same series of different individual target peptides joined together by innerconnecting peptides.
- the fifth form is composed of a series of tandem units linked together by intraconnecting peptides wherein each unit contains several identical or different target peptides joined by innerconnecting peptides and the target peptides do not repeat from unit to unit.
- the sixth form is composed of identical multiple tandem units wherein each unit contains several identical target peptides joined by innerconnecting peptides.
- the target peptide may incorporate all or a portion of any natural or synthetic peptide desired as a product, e.g., any desired protein, oligopeptide or small molecular weight peptide.
- a peptide includes at least two amino acid residues linked by a peptide bond.
- Suitable embodiments of the target peptide which may appear as single or multiple linked units in the variable fused polypeptide include caltrin, calcitonin, insulin, tissue plas inogen activator, growth hormone, growth factors, growth hormone releasing factors, erythropoietin, interferons, interleukins, oxytocin, vasopressin, ACTH, collagen binding protein, parathyroid hormone, glucagon like peptide, glucagon, proinsulin, tumor necrosis factor, substance P, brain naturetic peptide, individual heavy and light antibody chains, individual antibody chain fragments especially such as the isolated variable regions (VH or VL) as characterized by Lerner, Science, 246. 1275 et . seq. (Dec.
- polypeptides having physiologic properties such as sweetening peptides, mood altering polypeptides, nerve growth factors, regulatory proteins, functional hormones, enzymes, DNA polymerases, DNA modification enzymes, structural polypeptides, neuropeptides, polypeptides exhibiting effects upon the cardiovascular, respiratory, excretory, lymphatic, immune, blood, reproductive, cell stimulatory and physiologic functional systems, leukemia inhibitor factors, antibiotic and bacteriostatic peptides (such as cecropins, attacins, apidaecins) , insecticidal, herbicidal and fungicidal peptides as well as lysozymes.
- physiologic properties such as sweetening peptides, mood altering polypeptides, nerve growth factors, regulatory proteins, functional hormones, enzymes, DNA polymerases, DNA modification enzymes, structural polypeptides, neuropeptides, polypeptides exhibiting effects upon the cardiovascular, respiratory, excretory, lymphatic, immune, blood, reproductive
- variable fused polypeptides are peptides which include an amino acid sequence having the formula:
- the target peptide may include an amino acid sequence corresponding to GRF(1-41) (SEQ ID NO:23) , GLPK7-34) (SEQ ID NO:21) or PTH(l-34) (SEQ ID NO:22) .
- the - (CS1) - and -(CS2)- cleavage sites may be a chemical cleavage site or an enzymatic cleavage site.
- the enzymatic cleavage site may be recognized by an endopeptidase or by an exopeptidase (e.g., where r is 1 and the -(CS2)- is the C-terminal residue of the construct) .
- the enzymatic cleavage site is recognized by an endopeptidase.
- the fusion protein construct may include a chemical cleavage site or an enzymatic cleavage site.
- the cleavage site or sites which may be incorporated into the fusion protein construct will depend upon the identity of the target peptide (s) present.
- the cleavage site and target peptide are typically selected so that target peptide does not contain an amino acid sequence corresponding to the cleavage site. Secondary considerations will also influence the choice of a particular cleavage site.
- the cleavage sites may be designed so as to avoid the use of a enzymatic cleavage reaction.
- a chemical cleavage site such as a site which may by cleaved after treament with an S- cyanylating agent (e.g, 2-nitro-5-thiocyanatobenzoate) or by treatment with an acid having a pK a of no more than about 3.0.
- an S- cyanylating agent e.g, 2-nitro-5-thiocyanatobenzoate
- an acid having a pK a of no more than about 3.0 it may be desireable to employ a cleavage site which permits a modification of the target peptide to introduce a specific functional group, e.g., a C-terminal ⁇ -carboxamide group.
- Enterokinase (Asp) 4 ys GACGACGACGATAAA (SEQ ID NO:2) (SEQ ID NO:l) Factor Xa IleGluGlyArg ATTGAAGGAAGA (SEQ ID NO: ) (SEQ ID NO:3)
- Host cells transformed with an expression vector carrying a recombinant fusion protein construct gene may be employed to express the fusion protein construct.
- the host cell may be a prokaryotic or eukaryotic host cell or a cell in a higher organism.
- the host cell is a microbial host cell such as E. coli .
- the vector carrying the protein purification construct gene may be prepared by insertion of the DNA segments coding for the fusion protein construct into an appropriate base vector. Methods for expression of single- and multicopy recombinant fusion protein products are disclosed in International Application No. PCT/US91/04511, the disclosure of which is incorporated herein by reference.
- the expression vector incorporates the recombinant gene and base vector segments such as the appropriate regulatory DNA sequences for transcription, translation, phenotyping, temporal or other control of expression, RNA binding and post-expression manipulation of the expressed product.
- Structural features such as a promoter, an operator, a regulatory sequence and a transcription termination signal are generally included in the expression vector.
- the expression vector may be synthesized from any base vector that is compatible with the host cell or higher organism and provides the foregoing features.
- the regulatory sequences of the expression vector will be specifically compatible or adapted in some fashion to be compatible with prokaryotic or eukaryotic host cells or higher organisms.
- Post-expression regulatory sequences, which cause secretion of the polypeptide construct can be included in the eukaryotic expression vector.
- the expression vector exhibit a stimulatory effect upon the host cell or higher organism such that the polypeptide construct is overproduced relative to the usual biosynthetic expression of the host.
- the recombinant gene is inserted into an appropriate base vector which is used to transform host cells or higher organisms with the resulting recombinant vector.
- the fusion protein construct may be expressed within the host cell or higher organism as a soluble product or as a product that is insoluble in the cell .
- the fusion protein construct may be expressed as a secreted product by the host cell or higher organism.
- the fusion protein construct may be expressed in a host cell such as E. coli as a part of an inclusion body, i.e., an aggregate of insoluble material .
- Fusion protein constructs which are expressed as part of an inclusion body typically include two or more copies of a target peptide. It has been found that most single copy fusion protein constructs based on a carbonic anhydrase are expressed as a soluble product. For example, single copy fusion protein constructs which include hCAII and a single copy of a target peptide, such as calcitonin, substance P, angiotension, ATPase-IP, £SU ATPase, and asparagine synthetase, are expressed as soluble cell products in E. coli . Surprisingly, it has been discovered that in some instances, however, a single copy carbonic anhydrase- based fusion protein may be expressed as part of an inclusion body.
- fusion proteins which include hCAII and a single copy of GRF(1-41) (SEQ ID NO:23) , GLPK7-34) (SEQ ID N0:21) or PTH(l-34) (SEQ ID NO:22) are expressed as a part of an inclusion body in an E . coli host cell such as E. coli BL21 F ' ompT r " B m " B (DE3).
- the present invention provides a method of producing a recombinant peptide which includes precipitating either the fusion protein construct or a fragment of the fusion protein construct including the carbonic anhydrase (collectively a "CA-based protein”) .
- hCAII is known to precipitate when a solution at about neutral pH of the enzyme in its native form is acidified. It is believed that lowering the pH leads to a zinc cation being stripped out of the native enzyme and substantial conformational changes resulting in its precipitation.
- CA-based protein typically may be precipitated from a solution simply by adjusting the pH to between about 3.2 and about 6.0, preferably between about 3.5 and about 5.5, and more preferably between about 4.0 and about 5.0.
- CA-based proteins may also be precipitated from solutions having a high salt concentration, e.g., from solutions which include at least about 5% (w/v) sodium sulfate or at least about 5% (w/v) ammonium sulfate.
- a recombinant peptide is isolated by a process which includes precipitating the fusion protein construct.
- the precipitation step may be carried out with a fusion protein construct which has been expressed as a soluble product or with a fusion protein construct which has been expressed as a part of an inclusion body. In the latter instance, the inclusion body is dissolved prior to the precipitation step, e.g., in a solution which includes at least about 0.5M citric acid.
- the fusion protein construct may also be dissolved in a variety of other solutions, such as a solution containing a chaotropic agent (e.g., guanidine hydrochloride) or a detergent (e.g., SDS) , a solution containing at least about 2 M urea or a solution having a pH of at least about 10.0.
- a chaotropic agent e.g., guanidine hydrochloride
- a detergent e.g., SDS
- the fusion protein construct may be precipitated from the above solutions by adjusting the pH of the solution to between about 3.2 and about 6.0 and preferably to between about 3.5 and about 5.5.
- the efficiency of the precipitation may be enhanced in some cases by adding a salt to the solution in addition to adjusting the pH.
- Suitable salts include sodium chloride, potassium chloride, manganese sulfate, sodium sulfate, sodium acetate, and lanthanum chloride.
- divalent metal ions such as Mg 2* , Ca 2+ , Zn 2 *, Sr 2* or Co 2* together with the pH adjustment may also enhance the efficiency of the precipitation.
- solubilized fusion protein construct is precipitated from an alkaline solution
- the pH of the solution is typically adjusted by adding an acid such as acetic acid, formic acid, citric acid, phosphoric acid, and hydrochloric acid.
- the solubilized fusion protein construct may be also precipitated from solution simply by the addition of a sufficient amount of a salt such as sodium sulfate or ammonium sulfate. In some instances, it may be useful to remove cell debris and nucleic acid material from a crude cell lysate as an initial step in the isolation of a recombinant peptide.
- PEI polyethyleneimine
- the precipitated fusion protein may be resolubilized, e.g., by dissolution in a solution having a pH of at least about 10, and preferably at least about 10.5.
- the precipitated fusion protein may also be redissolved in other types of solutions, such as solutions which include a chaotropic agent, a detergent or at least about 0.5 M citric acid.
- the fragment containing the carbonic anhydrase (“carbonic anhydrase fragment") may be removed by chromatography, filtration, or preferably, by precipitation.
- the carbonic anhydrase fragment may be precipitated simply by again adjusting the pH of the solution to between about 3.5 and about 6.0.
- the carbonic anhydrase fragment may be separated from the cleavage products using a ligand immobilized affinity separation technique.
- the carbonic anhydrase fragment in native or renatured form, may be removed by contacting a solution of the cleavage products with an inhibitor (e.g., an affinity column) which includes benzenesulfonamide compound or an acetazolamide compound.
- an inhibitor e.g., an affinity column
- the benzenesulfonamide compound includes a sulfanilamide compound such as an amino substituted benzenesulfonamide (e.g., 4-amino- benzenesulfonamide) or a derivative thereof.
- the acetazolamide compound is 5-acetamido-l, 3 ,4-thiadiazol- 2-sulfonamide or a derivative thereof.
- the method of producing a recombinant peptide includes (i) cleaving the fusion protein construct to produce a soluble carbonic anhydrase fragment and a soluble variable fused polypeptide fragment, and (ii) precipitating the carbonic anhydrase fragment.
- the carbonic anhydrase fragment may include other amino acids residues in addition to the carbonic anhydrase. These other amino acid residues typically are derived from an interconnecting peptide present in the fusion protein construct. Suitable interconnecting peptides for use in the present invention include amino acid sequences containing a chemical or enzymatic cleavage site.
- the carbonic anhydrase fragment typically includes at least a portion of the interconnecting peptide or a derivative thereof.
- the derivative generally is produced as a byproduct of the cleavage reaction.
- a carbonic anhydrase fragment having a C-terminal homoserine residue may be created by cleavage of a fusion protein construct at the C-terminal peptide bond of a methionine residue.
- the supernatant fraction remaining after the precipitation of the carbonic anhydrase fragment may be isolated by centrifugation.
- the supernatant fraction contains the variable fused polypeptide fragment and, if desired, the variable fused polypeptide fragment purified further by conventional methods used for the isolation of peptides.
- the precipitated carbonic anhydrase fragment may be extracted with a solvent which includes an organic solvent.
- suitable solvents include an organic component such as acetonitrile, propanol, citric acid, polyethyleneglycol, or mixtures thereof.
- aqueous solutions including an organic solvent e.g., 50% aqueous acetonitrile and 50% aqueous n-propanol, may be used to carry out the extraction.
- the fusion protein construct Prior to being subjected to the cleavage reaction, the fusion protein construct may be purified by a variety of methods.
- the fusion protein construct may be purified using a ligand immobilized affinity separation technique or by precipitation. Purification of the fusion protein construct by precipitation is preferred as it allows the recombinant fusion protein construct to be produced by a process which relies solely on wet chemical separation processes such as precipitation, filtration or centrifugation without the need for renaturation or affinity purification.
- a third embodiment of the invention provides a method of producing a recombinant peptide which includes expressing the fusion protein construct as a part of an inclusion body in an E. coli host cell, and isolating the fusion protein construct.
- the fusion protein construct typically includes multiple copies of a target peptide.
- suitable single copy fusion proteins which may be expressed as inclusion bodies in an E.
- coli host cell are inclusion fusion proteins which include hCAII and a single copy of any one of GRF(1-41) (SEQ ID NO:23) , GRF(l-44) (SEQ ID NO:20) , GLPKl-34) (SEQ ID NO:26) , GLPK7-34) (SEQ ID NO-21) , GLPK7-36) (SEQ ID NO:27) , GLPK7-37) (SEQ ID NO:28) , PTH(l-34) (SEQ ID NO:22) , PTH(l-38) (SEQ ID NO:29) and PTH(l-84) (SEQ ID NO:25) .
- the inclusion bodies may be isolated from a crude cell lysate by conventional techniques, e.g., by centrifugation.
- the crude inclusion bodies may be subjected to an initial purification step such as washing the inclusion bodies with a 50mM Tris, ImM EDTA, pH 7.8 solution or a lOOmM EDTA solution to remove any cell debris and/or nucleic acid materials present.
- the inclusion bodies may be dissolved under a variety of conditions.
- the inclusion bodies may be dissolved under acidic conditions in a solution having a pH of no more than about 3.2 (e.g., in a solution which includes at least about 500mM citric acid) .
- the inclusion bodies may be dissolved in a solution which has a pH of at least about 10.
- the dissolution of the inclusion bodies under basic conditions may be facilitated by the addition of a small amount of a surfactant, such as N-lauroyl sarcosine, to the solution.
- a surfactant such as N-lauroyl sarcosine
- the inclusion bodies may also be dissolved in a solution which includes an effective amount of a chaotropic agent such as 6N HCl or urea, or a detergent such as N-lauroyl sarcosine, sodium dodecyl sulfate, sodium octyl sulfate or cetyl trimethyl ammonium bromide (CTAB) .
- a chaotropic agent such as 6N HCl or urea
- a detergent such as N-lauroyl sarcosine, sodium dodecyl sulfate, sodium octyl sulfate or cetyl trimethyl ammonium bromide (CTAB) .
- the solubilized fusion protein construct may be precipitated by adjusting the pH of the solution to between about 3.5 and about 6.0, and preferably to between about 4.0 and about 5.0.
- the solubilized fusion protein construct may be isolated by a process which includes a ligand immobilized affinity separation technique.
- Another embodiment of the invention includes cleaving the fusion protein construct to produce a carbonic anhydrase fragment and a variable fused polypeptide fragment and precipitating both the carbonic anhydrase fragment and the variable fused polypeptide fragment.
- the precipitated fragments may be extacted with a solvent which includes an organic component to recover the variable fused polypeptide fragment.
- Suitable solvents include an organic component such as acetonitrile, propanol, citric acid, polyethyleneglycol, or mixtures thereof.
- Example 1 Description of the Expression System Origin, phenotype and genotype of the host cells.
- E. coli BL21 F “ ompT r " B m ' B was obtained from Novagen, Inc., Madison, WI . These E. coli cells gave high levels of expression of genes cloned into expression vectors containing the bacteriophage T7 promoter.
- Bacteriophage (DE3) which contains the T7 RNA polymerase gene has been integrated into the chromosomal DNA of the BL21 (DE3) cells. The T7 RNA polymerase gene is controlled by the lacUV5 promoter and the lad gene product.
- Plasmid pET31FlmhCAII contains the coding region for hCAII (human carbonic anhydrase II) downstream of a bacteriophage T7 promoter in a pUC-derived plasmid backbone.
- Plasmid pAl was digested with the restriction endonucleases Ssp I and BspE I and the resulting ends were made blunt by treatment with T4 DNA polymerase.
- the DNA fragment from the pAl digest containing the T7- hCAII-cassette was subcloned into the Sea I restriction site of pBR322 (New England Biolabs) thus conferring tetracycline resistance, but not ampicillin resistance.
- the resulting plasmid was designated pBNl.
- the pAl plasmid was opened at the Hind III site and the EcoR V site and the synthetic oligonucleotide, 5' -A GCT GAA TTC AAC GTT CTC GAG GAT -3' (SEQ ID NO: 9) and its complementary sequence 5' -ATC CTC GAG AAC GTT GAA TTC-3' (SEQ ID NO:10) , were cloned into the vector.
- the insertion of these oligonucleotides provides a T7-hCAII- cassette containing unique EcoR I and Xho I restriction sites at the carboxyl terminal of hCAII.
- the resulting plasmid was designated pA3.
- the pBNl vector was digested with EcoR I and the single stranded overhangs were filled in with Polymerase I Large (Klenow) Fragment.
- the linear plasmid with newly formed blunt ends was religated, thus destroying the EcoR I site.
- the resulting plasmid was designated pBN3.
- Plasmid pA3 was digested with the restriction endonucleases, Xba I and BspE I.
- the DNA fragment from the pA3 digest containing the T7-hCAII-cassette was subcloned into the pBNl vector which had been digested with Xba I and BspE I .
- the resulting vector was designated plasmid pBN4.
- Example 2 Inoculum Preparation for hCA-Fusion Constructs L-broth was sterilized in the autoclave at 121°C for 20 minutes on the liquid cycle setting. The glucose and tetracycline stocks were filter sterilized by passage of the solution through a 0.22 ⁇ m filter. Two 250 ml shake flasks were each charged with the following solutions:
- the media contained the following: 1200.0 g Case amino acids; 300.0 g Yeast extract; 30.0 g NaCl; and 0.10 ml
- the fermentor was sterilized at 121°C for 25 minutes. The fermentor was cooled to 37°C. Before inoculation, the following solutions were added to the fermentor: glucose (480.0 g in 800.0 ml H 2 0) magnesium (120.0 g MgS0 4 -HO in 250.0 ml H 2 0) phosphates (120.0 g K 2 HP0 4 & 465.0 g KH 2 P04 in
- the media feed was started.
- the media feed consisted of 1200.0 g case amino acids and 300.0 g yeast extract dissolved in 5.0 L distilled H 2 0 and sterilized for 20 minutes on liquid cycle .
- the media feed was added to the fermentor over 1.0-1.5 hours.
- the fermentation was induced by adding the following solutions to the fermentor: isopropylthiogalactoside (IPTG; 28.8 g in 200 ml distilled H 2 0) ; ZnCl 2 (0.818g in 50 ml distilled H 2 0 with one drop of 6N HCl) .
- the IPTG solution was filter sterilized through 0.22 ⁇ m filter.
- the ZnCl 2 solution was sterilized for 20 minutes using the liquid cycle in the autoclave.
- the concentration of IPTG in the fermentor was 2.0 mM and the concentration of ZnCl 2 was 100 ⁇ .
- a feed of a mixture of amino acids was then started at this point.
- the amino acid feed consisted of 225.0 g L-serine; 75.0 g L-tyrosine; 74.0 g L-tryptophan; 75.0 g L-phenylalanine; 75.0 g L-proline; and 75.0 g L-histidine; and was dissolved in a mixture of 1.5 L H 2 0 and 500 ml concentrated HCl.
- the amino acid feed was sterile filtered through a 0.22 ⁇ m filter prior to addition to the fermentation. Induction was allowed to continue for 2.0 hours at which point the fermentation broth was transferred to a harvest tank and chilled to approximately 5-10°C. The fermentation typically yielded between 6.5 to 9.5 kg of wet cell paste (dry cell weight of about 1.0-1.5 kg) .
- Example 4 Harvest of 60 L Fermentation
- the cell suspension from the fermentor as desribed above was concentrated over a tangential crossflow membrane to a volume of 10 L.
- the concentrated cell suspension was diafiltered and washed with 30 L of a cold wash buffer containing 50 mM Tris-S04 pH 7.8, 1.0 mM EDTA, and 0.10 mM phenylmethylsulfonyl fluoride
- the cell suspension was then concentrated to 8 L. The concentration and washing of the cell suspension typically required 6-10 hours. At this point, the concentrated cell suspension (cell paste) may be bagged and frozen for later processing or transferred to homogenizer holding tanks for cell lysis.
- the cell paste obtained from the 60 L fermentor was diluted to 32 L in cold wash buffer (see above) and the resulting cell suspension was chilled to 5-10°C.
- the chilled cell suspension was homogenized at 12,000 psi with a Galin high pressure homogenizer.
- the homogenized cell paste was passed through a heat exchanger to chill the lysate to 10°C and passed through the homogenizer a second time.
- Example 6 Preparation of Thrombin Stock Solution
- the thrombin used in fusion protein cleavage reactions was obtained from Calbiochem in the form of a lyophilized powder. This powder was solubilized prior to use by dissolution in MilliQ water to a concentration of 1 mg/ml as determined by specific activity.
- the preparation of the DNA segment coding for a single copy PTH(l-34) (SEQ ID NO:22) fusion protein was carried out by preparing an expression vector coding for a PTH-construct which included a DNA segment coding for the hCAII, an interlinking peptide, and PTH(1-34) (SEQ ID NO:22) .
- the following oligos were obtained from Operon Technologies Inc, 1000 Atlantic Ave. Alameda CA 94501. Oligo 1: 5' CCC AAG CTT CTG TTC GTG GTC CGC GTT CTG
- Oligo 3 5' TCC AGC TGA TGC ACA ACC TGG GTA AAC ACC
- Oligo 8 5' CCG GAT ATC TTA GAA GTT GTG AAC GTC CTG
- CAG (SEQ ID NO:18) The eight synthetic DNA oligos were obtained and the complementary strands phosphorylated and annealed. The four double stranded fragments were used to prepare a DNA fragment coding for the interpeptide linker followed by PTHd-34) (SEQ ID NO:22) . This DNA fragment was digested and inserted into pAl using the restriction sites Hind III and EcoR V creating the vector pAl:PTH(l- 34) .
- the expression cassette was removed from pAl:PTH(l- 34) by digestion with the restriction endonucleases Xba I and BspE I and inserted into the vector pBNl which had been digested with the same restriction endonucleces. This final vector was desiganted pBNl :PTH (1-34) . E. coli cells transformed with the vector pBNl:PTH(1-34) containing DNA coding for an hCA-PTH fusion protein were prepared, cultured and lysed according to the procedures described above.
- the hCA- PTH fusion protein included hCAII linked to an amino acid sequence corresponding to PTH(1-34) (SEQ ID NO:22) through a thrombin cleavage site (Gly-Pro-Arg) immediately adjacent the N-terminus of the PTH(1-34) (SEQ ID NO:22) sequence.
- the hCA-PTH fusion protein was expressed as inclusion bodies in E. coli BL21 F " ompT r B m " B (DE3) cells.
- the cell lysate from the 60 L fermention run was centrifuged in a continuous flow rotor at 20,000 g at 400 ml/min.
- the pellet contained 300-500 g of crude inclusion bodies.
- the crude hCA-PTH inclusion bodies was suspended in 2M citic acid at a concentration of 60 mg solids/ml (4-8 liters) and sonicated at 70% power with a 50% pulse rate.
- the solubilized inclusion bodies were clarified by centrifugation at 20,000 g.
- the hCA-PTH fusion protein in the supernatant was precipitated by the addition of 10 N NaOH until the pH reaches 4-5.
- the precipitated hCA-PTH fusion protein was collected by centrifugation at 20,000 g.
- the precipitated hCA-PTH fusion protein was then washed with 4 to 8 liters of 5% acetic acid/45% EtOH in Milli-Q water and the precipitated hCA-PTH fusion protein was again collected by centrifugation.
- the hCA-PTH fusion protein was then washed twice with 4 to 8 liters of 100 mM EDTA and once with 4-8 liters of Milli Q water and the protein collected by centrifugation after each wash.
- a solution containing 200 ml of 50mM NaOH and 0.25% N-lauroyl sarcosine is added to a bottle containing a pellet of the hCA-PTH fusion protein.
- the bottles are placed into 37°C water bath to warm pellets (typically for 2-5 minutes) to aid in the solubilization of the pellet.
- the material is homogenized until all large pieces are disaggregated.
- the pH is readjusted 11.6 to 11.9 with a solution containing 50mM NaOH and 0.25% N- lauroyl sarcosine.
- the resulting solution is sonicated until all of the hCA-PTH fusion protein pellet has dissolved.
- the protein concentration of the reaction solution is determined by absorbance at 280 nm. Ideally the concentration should be 6-7 mg/ml (8-10 liters for a 60 1 fermentation) . If the concentration is greater than 9 mg/ml, the solution is diluted to 6-7 mg/ml with the 50mM NaOH/0.25% N-lauroyl sarcosine solution. The protein solution is stirred vigorously and the pH is adjust to 8-8.2 with 1M Tris-HCl. If solution is hazy, it is filtered through glass fiber filters.
- the solution is then filtered through 0.45 ⁇ m cellulose acetate membrane and the protein concentration is determined by measuring the absorbance at 280 nm.
- Solid NaCl is added to a final concentration of 250mM.
- a thrombin stock solution 1 mg/ml is added to produce a protein to enzyme ratio of 5000:1 w/w.
- the solution is then stirred in a water bath plate at 37°C.
- the reaction is monitored by HPLC on a C8 column eluted with a gradient from Buffer A (95% water, 5% acetonitrile (ACN) , 0.1% trifluoroacetic acid (TFA) ) to Buffer B (95% ACN, 5% water, .1% TFA) .
- Buffer A 95% water, 5% acetonitrile (ACN) , 0.1% trifluoroacetic acid (TFA)
- Buffer B 95% ACN, 5% water, .1% TFA
- reaction is complete as determined by the loss of the peak corresponding to the starting material in 46-48 hours.
- the PMSF is dissolved into 95% EtOH, and added directly to the reaction mixture with vigorous stirring.
- the thrombin cleavage procedure yields 5.1 g of PTH(1-34) (SEQ ID NO:22) from 60 g of hCA-PTH fusion protein.
- Both the resulting human carbonic anhydrase (from the cleavage of the hCA-PTH fusion protein) and remaining unhydrolized fusion protein are precipitated from the solution by adding sufficient citric acid to achieve 150mM, leaving the desired peptide (PTH 1-34) (SEQ ID NO:22) in solution.
- the precipitated material is removed by centrifugation.
- the supernatant is filtered through 0.45 ⁇ m filter and frozen at -80°C or desalted directly on a C8 column.
- the yield from the peptide from the step is 85%.
- the PTH (1-34) may be further purified by chromatography on preparative C8 column using a gradient from 10-70% Buffer B of aqueous acetonitrile/ trifluoroacetic acid (ACN/TFA) buffers, where Buffer A: 0.1% TFA, 95% water, 5% acetonitrile, Buffer B:0.1% TFA, 5% water, 95% acetonitrile.
- the PTH(l-34) (SEQ ID NO:22) sample may be purified on the preparative C8 column eluting first with a gradient from 10-70% Buffer B; where Buffer A is 5mM HCl, 95% water, 5% acetonitrile and Buffer B.
- the PTH(l-34) (SEQ ID NO:22) is desalted with a gradient where Buffer A lOmM acetic acid, and Buffer B i- 10 mM acetic acid in 50% aqueous ethanol.
- Oligopair 1&2 were inserted into pUC19 (commercially available from
- Oligopair 3&4 was then inserted into this vector between
- Oligopair 5&6 was ligated into pBluescript IISK+
- the fragment containing oligopair 5&6 was inserted into pUC19:GLP(7-22) by digesting pUC19 :GLP (7-22) with Nar 1 and EcoR I and digesting PB5 :GLP(21-34)AFA with Cla I and EcoR I and ligating the fragment from PB5:GLP(21- 34)AFA containing oligos 5&6 into the truncated pUC19:GLP(7-22) to yield pUC19 :GLP (7-34)AFA.
- pUC19:GLP(7-34)AFA was digested with Hind III and the fragment containing the sequence coding for the peptide interlinker followed by GLP1 (7-34) -Ala-Phe-Ala (SEQ ID NO:30) ("GLP1 (7-34)AFA") was transferred to pA4 to yield vector pA4 :GLP (7-34)AFA.
- the hCAII gene in pA4 had been mutated to change the methionine-240 to a cysteine.
- the expression cassette was then digested from pA4:GLP(7-
- the hCA-GLPl-AFA fusion protein included hCAII linked to an amino acid sequence corresponding to GLP1 (7-34) -Ala-Phe-Ala (SEQ ID NO:30) through a methionine residue located immediately adjacent the N-terminus of the GLP1 (7-34) -Ala-Phe-Ala (SEQ ID NO:30) sequence.
- the hCA-GLPl-AFA fusion protein was expressed as inclusion bodies in E. coli BL21 F " ompT r B m ' B (DE3) cells.
- the cell lysate was centrifuged in a continuous flow rotor at 20,000 g at 400 ml/min to produce a pellet containing 300-500 g of crude inclusion bodies.
- the crude hCA-GLPl-AFA inclusion bodies were suspended in lysis buffer at a concentration of 25% solids (1.2-2.0 L) and homogenized in the Galin homogenizer at 13,000 psi .
- the homogenized inclusion bodies were collected by centrifugation at 20,000 g, resuspended in a solution of 100 mM Na Acetate pH 4.5 and homogenized a second time.
- the homogenized inclusion bodies were then suspended in distilled water.
- the resulting suspension is homogenized and the inclusion bodies collected by centrifugation.
- the purified inclusion bodies are dissolved in 1.5 M citric acid and clarified by centrifugation.
- the hCA-GLPl-AFA fusion protein was precipitated by the addition of NaOH until the pH is 4-5 and isolated by centrifug
- the hCA-GLPl-AFA inclusion bodies were dissolved in a solution of 2.0 M Citric Acid at a concentration of about 35-45 mg/ml.
- the solution was adjusted pH to 1.0 with cone.
- HCl and 0.2 g cyanogen bromide (CNBr) per g of total protein was added.
- the protein concentration was determined by HPLC.
- the protein solution was sparged with pure Argon before addition of the CNBr.
- the cleavage reaction was allowed to proceed under an Argon atmosphere for 4-5 hours at which time residual CNBr was neutralized by adding 2.2g D,L-methionine per g of CNBr added followed by stirring for 30 minutes.
- the solution from the CNBr cleavage reaction was diluted 1:1 with a solution of 10% sodium sulfate (w/v) in water to precipitate all protein and peptide from the solution.
- the sample was centrifuged at 20,000 x g for 15 minutes and the supernatant decanted. Distilled water (200 ml) was added to each centrifuge vial. The resulting mixture was homogenized and centrifuged for 15 min. at 20,000 x g. The supernatant was decanted and a volume of 50% acetonitrile (ACN) was added to the pellet material.
- ACN 50% acetonitrile
- the extraction with the 50% acetonitrile solution was repeated two to three times to achieve a 90-95% recovery of GLPl (7-34)AFA (SEQ ID NO:30) in the acetontrile solution.
- the extraction may also be carried out with 50% n-propanol .
- the 50% ACN solution is diluted to 12.5% ACN with distilled H 2 0 to facilitate the binding of GLPl (7-34) -AFA (SEQ ID NO:30) to the C8 resin.
- the peptide solution is loaded onto the C8 resin in an low pressure column and the column is washed with 5 column volumes of 30% (v/v) ACN solution.
- the GLPl (7-34) -AFA (SEQ ID NO:30) is then eluted with a solution of 50% ACN in distilled H 2 0.
- the 50% ACN solution is lyophilized to obtain the GLPl (7- 34) -AFA (SEQ ID NO:30) .
- GLPl (7-34)AFA (SEQ ID NO:30) (1 mmole) is dissolved in a 50/50 (v/v) solution of DMF/H 2 0 which includes 5 mM
- the GLPl (7-36) -NH 2 may be further purified by chromatography on preparative C8 column using a gradient of aqueous acetonitrile/trifluoroacetic acid (ACN/TFA) buffers.
- ACN/TFA aqueous acetonitrile/trifluoroacetic acid
- Example 9 Production of GRF(1-44)NH 7 (SEQ ID NO:20) Eight oligonucleotides containing segments of the linker and the peptide were phosphorylated and complementary oligonucleotide pairs 1&2, 3&4, 5&6, and 7&8 were annealed. Oligonucleotide pairs l ⁇ -2 and 3&4 were simultaneously ligated into the pTZ19R vector (commercially available from Pharmacia Biotech Inc., NJ) between the Hind III and Sal I sites to yield pTZ:GRF(l- 29) .
- pTZ19R vector commercially available from Pharmacia Biotech Inc., NJ
- Oligonucleotide pairs 5&6 and 7&8 were simultaneously ligated into a separate pTZ19R vector between the Sal I and EcoR I sites to yield pTZ:GRF(29- 44)A.
- the gene fragments were cloned adjacent to each other in a single vector by digesting pTZ:GRF(1-29) and pTZ:GRF (29-44)A with the restriction endonucleases Xmn I and Sal I, isolating the 1.9 kb band from the pTZ:GRF(l- 29) vector and the 0.9 kb band of the pTZ :GRF (29-44)A vector and ligating them together to yield the vector pTZ:GRF(l-44)A.
- the pA2 vector was digested with EcoR V.
- pTZ:GRF(l-44)A was digested with Dra I and EcoR V.
- the fragment containing the GRF gene and the linearized pA2 plasmid were ligated together to yield pBN2 :GRF(1-44)A.
- E. coli cells transformed with vector pBN2:GRF(l- 44)A containing DNA coding for an hCA-GRF fusion protein were prepared, cultured and lysed according to the procedures described above.
- the hCA-GRF fusion protein included hCAII linked to an amino acid sequence corresponding to GRF (1-44) -Ala (SEQ ID N0:31) through an interconnecting peptide.
- the interconnecting peptide included a thrombin cleavage site and an enterokinase cleavage site.
- the enterokinase cleavage site (Asp-Asp- Asp-Asp-Lys) (SEQ ID NO:2) was positioned immediately adjacent the N-terminus of the GRF(l-44) -Ala (SEQ ID NO:31) sequence.
- the thrombin cleavage site (Gly-Pro- Arg) was located so that after treatment with thrombin, the hCA-GRF fusion protein produced a peptide fragment having an 8 amino acid sequence (Ala-Met-Val-Asp-Asp- Asp-Asp-Lys) (SEQ ID NO:19) connected to the N-terminus of the GRF (1-44) -Ala (SEQ ID N0:31) sequence.
- the hCA- GRF fusion protein was expressed as inclusion bodies in E. coli BL21 F " ompT r " B m " B (DE3) cells.
- the cell lysate was centrifuged in a continuous flow rotor at 20,000 g at 400 ml/min to produce a pellet containing 300-500 g of crude inclusion bodies.
- the crude hCA-GRF-Ala inclusion bodies were suspended in 2M citic acid at a concentration of 60 mg solids/ml (5-9 L) and sonicated at 70% power with a 50% pulse rate.
- the solubilized inclusion bodies were clarified by centrifugation at 20,000 g.
- the hCA-GRF-Ala fusion protein in the supernatant was precipitated by the addition of 10 N NaOH until the pH reaches 4-5.
- the precipitated hCA-GRF-Ala fusion protein was then collected by centrifugation at 20,000 g. After washing with 5% acetic acid/ 45% ethanol in Milli-Q H 2 0, the precipitated hCA-GRF-Ala fusion protein was again collected by centrifugation. The precipitated hCA-GRF- Ala fusion protein was then resuspended twice in 100 mM EDTA and the fusion protein was collected by centrifugation. The washed, precipitated hCA-GRF-Ala fusion protein was suspended in distilled H 2 0. The suspension was homogenized and the hCA-GRF-Ala fusion protein was collected by centrifugation.
- a 200 ml portion of a solution containing 50mM NaOH and 0.25% N-lauroyl sarcosine was added to a bottle containing a pellet of the hCA-GRF-Ala fusion protein.
- the bottle was placed into 37°C water bath to warm the pellet.
- the NaOH solution was swirled around in the bottle to remove all solid material from the bottle sides.
- the slurry was then poured into a suitable size beaker.
- the material was homogenized until all large pieces are disaggregated and the pH was monitored. The pH was readjusted to between 11.6 and 11.9 with a solution of 50mM NaOH and 0.25% N-lauroyl sarcosine.
- the solution was sonicated until all of the inclusion body pellet has dissolved and solution is clear. Sonication times varied according to size of batch. Typically anything over 1 liter was sonicated for 2 minutes, power 10, pulser on, 70% duty cycle (smaller batches required less time) .
- the protein concentration of the reaction solution was measured. If concentration was greater than 9 mg/ml, the solution was diluted with the 50mM NaOH/0.25% N-lauroyl sarcosine solution to a protein concentration of 6-7 mg/ml. The protein solution was stirred vigorously, and the pH adjusted to 8-8.2 with 1M Tris- HC1. If the solution was slightly hazy at this point, the solution was clarified by filtering through glass fiber filters. The clarified solution was sterile filtered through a 0.45 ⁇ m cellulose acetate membrane. The protein concentration was determined by measuring the absorbance at 280 nm. Sufficient NaCl to produce a 250mM NaCl concentration was added with vigorous stirring.
- thrombin stock solution (1 mg/ml) to produce a protein to enzyme ratio of 5000:1 was added and the resulting mixture stirred in a water bath on top of stir plate at 37°C.
- the reaction was monitored by HPLC on a C8 column eluted with a gradient of H 2 0/ACN/TFA buffers.
- the reaction was stopped by the addition of PMSF to a final concentration of 0. ImM when the fusion construct peak was essentially gone (usually 46-48 hours) .
- the PMSF was dissolved into 95% EtOH and added directly to the reaction mixture with vigorous stirring.
- Citric Acid Precipitation of the hCA-Fragment The human carbonic anhydrase fragment from the cleavage of the fusion protein and any residual uncut fusion protein were removed from solution by precipitation with 90mM citric acid, leaving the intermediate peptide, Ldr-GRF (1-44 ) -Ala, in solution.
- the volume of the thrombin cut solution was measured in a graduated cylinder. A stock solution of 1M citric acid was added to final concentration of 90mM citrate. The addition was made slowly while with vigorously stirring the solution. The aggregated material was centrifuged and the supernatant was filtered through a 0.45 ⁇ m filter. The filtered supernatant was either frozen at -80°C or run directly onto a C8 column for desalting.
- the pellets from the precipitation were washed with a solution of 90 mM citrate pH 3.0-3.1. Between 150-200 ml of citrate solution was added to each pellet of 1-2 grams of hCA. The pellets were homogenized and the supernatant from the wash was filtered through a 0.45 ⁇ m filter and saved. The washed pellets were discarded. The supernatant was either frozen at -80°C or desalted directly on a C8 column.
- the 90 mM citric acid solution of Ldr-GRF (1-44) -Ala was loaded directly onto a preparative C8 column.
- the column was eluted with a gradient of aqueous ethanol/acetic acid buffers.
- the fractions containing the Ldr-GRF (1-44) -Ala were collected (typically 90-95% pure) and the solution concentrated by evaporation to 21-25 mg/ml.
- the resulting solution was stored at -80°C prior to transpeptidation.
- the concentration Ldr-GRF (1-44) -Ala peptide was determined by C8 HPLC using 1 mM GRF standard.
- the peptide solution was diluted to a concentration of 3 mM Ldr-GRF(1-44) -Ala (18.0 mg/ml) with water.
- EDTA and sodium phosphate were added (to 5 mM; 1.9 mg/ml and 25 mM; 3.6 mg/ml respectively) and the pH was adjusted to 6.0 with 1 M NaOH.
- 2-Nitrophenylglycinamide [ONPGA] 250 mM; 89.0 m g/ml was added and the pH was again adjusted to 6.0 with 1 M NaOH.
- Carboxypeptidase-Y (“CPD-Y”; 2 ⁇ l/ml) was the added and stirring was in the dark at 35-40 °C. The extent of reaction to produce Ldr-GRF-ONPGA was monitored by HPLC. After about 1-2 hours the reaction was stopped by the addition of acetonitrile to a final concentration of 15% v/v.
- the sample from the CPD-Y transpeptidation was loaded onto a C8 HPLC column and rinsed with a 20% ethanol, 10 mM sodium phosphate, pH 6.8 buffer to remove unreacted ONPGA.
- the column was then eluted with a 50% EtOH, 10 mM Sodium Phosphate, pH 6.8 buffer and the Ldr- GRF-ONPGA peak was collected.
- the concentration of the Ldr-GRF-ONPGA peptide was determined by C8 HPLC using 1 mM GRF standard and the concentration was diluted to 1 mM Ldr-GRF-ONPGA (6.0 mg/ml) with 50% ethanol.
- Sodium bisulfite (to 5 mM) and sodium benzoate (to 50 mM ) were added and the solution is adjusted to pH 9.5 with 1 M NaOH.
- the mixture was irradiated (wavelength >305 nm; 200-210 W medium pressure mercury lamp) while being maintained in a 20-25 °C circulating water bath. During the reaction a constant flow of Argon was maintained and the reaction was constantly stirred. The reaction was monitored by HPLC. After about 1-2 hours reaction was stopped by lowering the pH to 5.5 with acetic acid.
- Ldr-GRF-NH2 Enterokinase Cleavage Protocol
- the solution of Ldr-GRF-NH2 from the photolysis reaction was diluted 1:5 with water (1.0 mg/ml peptide) .
- Triton X-100 was added to a final concentration of 0.1%.
- Succinic acid and calcium chloride were added to produce concentrations of 50 mM (5.9 mg/ml) and 2 mM (0.3 mg/ml) respectively and the solution pH was adjusted to 5.5 with 10 M NaOH. After the solution was filtered through a 0.45 ⁇ m membrane, 5.0 mg/ml Dowex 1 resin was added.
- the Dowex 1 resin an anion exchange resin, was added to the reaction to bind the peptide containing the Asp-Asp- Asp-Asp (SEQ ID NO:32) sequence. This was found to increase both the rate of the reaction and the overall yield, as well as reduce the concentration of enterokinase required while improving substrate specificity.
- a 1:3000 ratio of enterokinase enzyme (1 ul per 10 mg peptide) was added and the reaction was maintained in a 35-40 °C water bath with constant stirring. After 20-24 hours, the cleavage reaction which converts the Ldr-GRF-NH2 into GRF (1-44) -NH2 (SEQ ID NO:20) reached 70-80% completion.
- DNA coding for a hCA-9AA fusion protein may be prepared and cultured according to the procedures described above.
- the hCA-9AA fusion protein includes hCAII linked to the amino acid sequence Thr-Asn-Thr-Gly-Ser-Gly-Thr-
- Pro-Ala (SEQ ID NO:33) through an interconnecting peptide.
- the interconnecting peptide includes an enterokinase cleavage site positioned immediate adjacent the N-terminus of the 9AA (SEQ ID NO:33) sequence.
- the hCA-9AA fusion protein may be expressed as a soluble protein in E. coli BL21 F " ompT r ' B m " B (DE3) cells.
- the cell paste from the fermentor is diluted with cold wash buffer and chilled to 5-10°C.
- the chilled cell suspension is homogenized at 12,000 psi with Galin high pressure homogenizer.
- the cell paste is passed through a heat exchanger and chilled to 10°C prior to a second pass through the homogenizer.
- a PMSF stock solution in 95% ethanol is added to a final concentration of 0.05 mM PMSF.
- the lysate is cooled to about 8°C, passed through the homogenizer at 12,000 psi and drained into a holding tank. After passing the lysate through the homogenizer at 12,000 psi yet another time, a 5% v/v pH 7.5 solution of polyethyleneimine (PEI) may be added to a total concentration of 0.35% PEI.
- PEI polyethyleneimine
- the resulting mixture is stirred for 20 minutes and clarified by Westfalia at 20,000 x g. The clarified solution is filtered through a 0.22 micro ⁇ m Pall filter system.
- a affinity column including p-aminomethylbenzene- sulfonamide-agarose resin is equilibrated with a 0.1M Tris-S0 4 pH 8.7 solution.
- the clarified supernatant from the PEI precipitation is loaded onto the column and the column is eluted with a series of Tris-S0 4 buffer solutions.
- the column fractions containing the fusion protein construct are pooled.
- the protein construct is precipitated from the pooled fractions by lowering the pH of the solution to 4.0 with glacial acetic acid.
- the precipitated fusion protein construct may be isolated by centrifugation and lyophilized.
- the precipitated fusion protein construct is dissolved in a ph 8.0 buffer solution containing 50mM Tris and ImM CaCl 2 .
- the mixture is sonicated until all the fusion protein construct has been dissolved.
- 5.0 mg/ml Dowex 1 resin was added.
- a 1:3000 ratio of enterokinase enzyme (1 ul per 10 mg peptide) was added and the reaction was maintained in a 35-40 °C water bath with constant stirring for 20-24 hours.
- the reaction mixture was filtered to remove the Dowex 1 and the reaction was stopped by the addition of acetonitrile to a final concentration of 15%.
- MOLECULE TYPE protein
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE protein
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (i) ORIGINAL SOURCE: (xi)
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE Genomic DNA
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE (vi) ORIGINAL SOURCE:
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
- MOLECULE TYPE peptide
- HYPOTHETICAL NO
- ANTISENSE NO
- FRAGMENT TYPE internal
- ORIGINAL SOURCE
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU44158/96A AU700605B2 (en) | 1994-12-07 | 1995-12-07 | Production of peptides using recombinant fusion protein constructs |
JP8517724A JPH10510155A (ja) | 1994-12-07 | 1995-12-07 | 組み換え融合蛋白構築物を用いるペプチドの製造方法 |
EP95942995A EP0796335A1 (fr) | 1994-12-07 | 1995-12-07 | Production de peptides au moyen de proteines de fusion de recombinaison |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35053094A | 1994-12-07 | 1994-12-07 | |
US08/350,530 | 1994-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996017942A1 true WO1996017942A1 (fr) | 1996-06-13 |
WO1996017942A9 WO1996017942A9 (fr) | 1996-08-15 |
Family
ID=23377117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/015800 WO1996017942A1 (fr) | 1994-12-07 | 1995-12-07 | Production de peptides au moyen de proteines de fusion de recombinaison |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0796335A1 (fr) |
JP (1) | JPH10510155A (fr) |
AU (1) | AU700605B2 (fr) |
CA (1) | CA2206848A1 (fr) |
WO (1) | WO1996017942A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1016723A1 (fr) * | 1998-12-21 | 2000-07-05 | Eli Lilly And Company | Fabrication recombinante de beta-Lipotropine et autres peptides |
WO2003076456A2 (fr) * | 2002-03-12 | 2003-09-18 | Dsm Ip Assets B.V. | Procede de recuperation de proteines par precipitation |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6703484B2 (en) | 1997-01-08 | 2004-03-09 | Invitrogen Corporation | Methods for production of proteins |
EP1539210A2 (fr) * | 2002-09-06 | 2005-06-15 | Bayer Pharmaceuticals Corporation | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
WO2008122089A1 (fr) * | 2007-04-05 | 2008-10-16 | The University Of Queensland | Procédé de purification de peptides recombinés par précipitation sélective |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
US9145450B2 (en) | 1998-10-23 | 2015-09-29 | Amgen Inc. | Thrombopoietic compounds |
US9733212B2 (en) | 2006-07-21 | 2017-08-15 | Life Technologies Corporation | Sharply resolving labeled protein molecular weight standards |
CN113340691A (zh) * | 2021-06-05 | 2021-09-03 | 清华大学 | 一种提取海洋沉积物中不同赋存形态磷的方法 |
US11261472B2 (en) | 2016-12-30 | 2022-03-01 | Universidad De Chile | Peptide sequence of a guide protein for the production of a peptide of interest, an expression vector, a host cell, and a method for the production of a peptide of interest |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200643033A (en) * | 2005-03-08 | 2006-12-16 | Chugai Pharmaceutical Co Ltd | Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007086A1 (fr) * | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Sequences d'amorce pour la production de proteines recombinantes |
WO1988007085A1 (fr) * | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Procede de purification de polypeptides recombinants |
WO1992000993A1 (fr) * | 1990-07-10 | 1992-01-23 | California Biotechnology Inc. | Isolation et purification de proteine de surfactant pulmonaire |
WO1992001707A1 (fr) * | 1990-07-16 | 1992-02-06 | Bionebraska, Inc. | Clonage de peptides destine a la purification |
EP0528686A2 (fr) * | 1991-08-19 | 1993-02-24 | Suntory Limited | Procédé pour la production de peptides |
-
1995
- 1995-12-07 WO PCT/US1995/015800 patent/WO1996017942A1/fr not_active Application Discontinuation
- 1995-12-07 AU AU44158/96A patent/AU700605B2/en not_active Ceased
- 1995-12-07 CA CA 2206848 patent/CA2206848A1/fr not_active Abandoned
- 1995-12-07 EP EP95942995A patent/EP0796335A1/fr not_active Withdrawn
- 1995-12-07 JP JP8517724A patent/JPH10510155A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007086A1 (fr) * | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Sequences d'amorce pour la production de proteines recombinantes |
WO1988007085A1 (fr) * | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Procede de purification de polypeptides recombinants |
WO1992000993A1 (fr) * | 1990-07-10 | 1992-01-23 | California Biotechnology Inc. | Isolation et purification de proteine de surfactant pulmonaire |
WO1992001707A1 (fr) * | 1990-07-16 | 1992-02-06 | Bionebraska, Inc. | Clonage de peptides destine a la purification |
EP0528686A2 (fr) * | 1991-08-19 | 1993-02-24 | Suntory Limited | Procédé pour la production de peptides |
Non-Patent Citations (1)
Title |
---|
VAN HEEKE, GINO ET AL: "Gene fusions with human carbonic anhydrase II for efficient expression and rapid single-step recovery of recombinant proteins: Expression of the Escherichia coli F1-ATPase.epsilon. subunit", PROTEIN EXPRESSION PURIF. (1993), 4(4), 265-74 CODEN: PEXPEJ;ISSN: 1046-5928, 1993, XP000568594 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7223566B2 (en) | 1997-01-08 | 2007-05-29 | Invitrogen Corporation | Methods for production of proteins |
US9409942B2 (en) | 1997-01-08 | 2016-08-09 | Life Technologies Corporation | Methods for production of proteins |
US8519099B2 (en) | 1997-01-08 | 2013-08-27 | Life Technologies Corporation | Methods for production of proteins |
US8389681B2 (en) | 1997-01-08 | 2013-03-05 | Life Technologies Corporation | Methods for production of proteins |
US6703484B2 (en) | 1997-01-08 | 2004-03-09 | Invitrogen Corporation | Methods for production of proteins |
US8012715B2 (en) | 1997-01-08 | 2011-09-06 | Life Technologies Corporation | Methods for production of proteins |
US7265206B2 (en) | 1997-01-08 | 2007-09-04 | Invitrogen Corporation | Methods of production of proteins |
US7259242B2 (en) | 1997-01-08 | 2007-08-21 | Invitrogen Corporation | Methods for production of proteins |
US7189827B2 (en) | 1998-10-23 | 2007-03-13 | Amgen Inc. | Modified peptides as therapeutic agents |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7169905B2 (en) | 1998-10-23 | 2007-01-30 | Amgen Inc. | Modified peptides as therapeutic agents |
US7166707B2 (en) | 1998-10-23 | 2007-01-23 | Amgen Inc. | Modified peptides as therapeutic agents |
US9534032B2 (en) | 1998-10-23 | 2017-01-03 | Amgen Inc. | Thrombopoietic compounds |
US9145450B2 (en) | 1998-10-23 | 2015-09-29 | Amgen Inc. | Thrombopoietic compounds |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1016723A1 (fr) * | 1998-12-21 | 2000-07-05 | Eli Lilly And Company | Fabrication recombinante de beta-Lipotropine et autres peptides |
US7847079B2 (en) | 2001-12-21 | 2010-12-07 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9221896B2 (en) | 2001-12-21 | 2015-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8252739B2 (en) | 2001-12-21 | 2012-08-28 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8513189B2 (en) | 2001-12-21 | 2013-08-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8071539B2 (en) | 2001-12-21 | 2011-12-06 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US8993517B2 (en) | 2001-12-21 | 2015-03-31 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US9296809B2 (en) | 2001-12-21 | 2016-03-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003076456A3 (fr) * | 2002-03-12 | 2003-12-24 | Dsm Ip Assets Bv | Procede de recuperation de proteines par precipitation |
WO2003076456A2 (fr) * | 2002-03-12 | 2003-09-18 | Dsm Ip Assets B.V. | Procede de recuperation de proteines par precipitation |
EP1539210A2 (fr) * | 2002-09-06 | 2005-06-15 | Bayer Pharmaceuticals Corporation | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
EP1539210A4 (fr) * | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | Agonistes modifies du recepteur glp-1 et leurs procedes pharmacologiques d'utilisation |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
US10188740B2 (en) | 2005-08-12 | 2019-01-29 | Amgen Inc. | Modified Fc molecules |
US11266744B2 (en) | 2005-08-12 | 2022-03-08 | Amgen Inc. | Modified Fc molecules |
US9733212B2 (en) | 2006-07-21 | 2017-08-15 | Life Technologies Corporation | Sharply resolving labeled protein molecular weight standards |
US10302591B2 (en) | 2006-07-21 | 2019-05-28 | Life Technologies Corporation | Sharply resolving labeled protein molecular weight standards |
WO2008122089A1 (fr) * | 2007-04-05 | 2008-10-16 | The University Of Queensland | Procédé de purification de peptides recombinés par précipitation sélective |
US11261472B2 (en) | 2016-12-30 | 2022-03-01 | Universidad De Chile | Peptide sequence of a guide protein for the production of a peptide of interest, an expression vector, a host cell, and a method for the production of a peptide of interest |
CN113340691A (zh) * | 2021-06-05 | 2021-09-03 | 清华大学 | 一种提取海洋沉积物中不同赋存形态磷的方法 |
CN113340691B (zh) * | 2021-06-05 | 2023-12-12 | 清华大学 | 一种提取海洋沉积物中不同赋存形态磷的方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0796335A1 (fr) | 1997-09-24 |
AU700605B2 (en) | 1999-01-07 |
AU4415896A (en) | 1996-06-26 |
CA2206848A1 (fr) | 1996-06-13 |
JPH10510155A (ja) | 1998-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU605291B2 (en) | Process for the purification of recombinant polypeptides | |
AU710695C (en) | Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs | |
CA2237296C (fr) | Procede de preparation de peptides par l'intermediaire de proteines de fusion issues de la streptavidine | |
US7105638B1 (en) | Product and process for the production, isolation, and purification of recombinant polypeptide | |
AU765206B2 (en) | Process for producing peptide with the use of accessory peptide | |
AU700605B2 (en) | Production of peptides using recombinant fusion protein constructs | |
WO1996017942A9 (fr) | Production de peptides au moyen de proteines de fusion de recombinaison | |
US6051399A (en) | Production of C-terminal amidated peptides from recombinant protein constructs | |
US20160168226A1 (en) | Process for production of insulin and insulin analogues | |
CA2159079C (fr) | Methodes et systemes d'expression de l'adn, utilises pour la surexpression de proteines dans des cellules hotes | |
US5334532A (en) | PDGF-B fusion protein, vectors, and host cells for use in production thereof | |
CA2324513A1 (fr) | Proteine chimere contenant une sequence de type chaperon intramoleculaire et son application dans la production d'insuline | |
US20030144471A1 (en) | Method for making acylated polypeptides | |
CN114380903B (zh) | 一种胰岛素或其类似物前体 | |
KR100368073B1 (ko) | 융합파트너를 이용한 재조합 단백질의 제조방법 | |
JP4386722B2 (ja) | アシル化されたポリペプチドの製造方法 | |
US20090035815A1 (en) | Synthetic Gene for Enhanced Expression in E. Coli | |
KR20040007892A (ko) | 재조합 인간 훼리틴 단백질 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 41-51,DESCRIPTION,REPLACED BY NEW PAGES 41-52;PAGES 52-61,CLAIMS,RENUMBERED AS PAGES 52/1 AND53-61;DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2206848 Country of ref document: CA Ref country code: CA Ref document number: 2206848 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995942995 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995942995 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995942995 Country of ref document: EP |